Vertex Gets Positive CHMP Opinion for Kaftrio/Kalydeco Combo

Vertex Pharmaceuticals Inc. on Friday said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Kaftrio in combination with Kalydeco in people ages 12 and older with cystic fibrosis with the most common genotypes.

The Boston drug maker said the combination, if approved by the European Commission, would be the first cystic fibrosis transmembrane conductance regulator modulator for people with one F508del mutation and one minimal function mutation and would bring additional benefit to people with two F508del mutations.

The European Commission generally follows the CHMP’s recommendations.

https://www.marketscreener.com/VERTEX-PHARMACEUTICALS-11321/news/Vertex-Pharmaceuticals-Gets-Positive-CHMP-Opinion-for-Kaftrio-Kalydeco-Combination-30829596/